

Summary of FDA Nearsighted Surgical Results Data for All LASIK Approved Excimer Laser Systems

Uncorrected Vision 20/20 or better at 6 Months Post-op Based on Initial Prescription

n=number of eyes treated

	-1.00 to -1.99D	-2.00 to -2.99D	-3.00 to -3.99D	-4.00 to -4.99D	-5.00 to -5.99D	-6.00 to -6.99D	-7.00D and above
Autonomous Ladarvision*	62.1% (n=29)	73.4% (n=64)	48.9% (n=47)	59.6% (n=52)	40.5% (n=37)	27.8% (n=18)	49.1% (n=53)
B+L Technolas 217**	85.7% (n=21)	90.4% (n=73)	83.8% (n=80)	84.0% (n=81)	84.2% (n=57)	77.5% (n=40)	90.0% (n=10)
LaserSight	55.6% (n=9)	51.5% (n=33)	67.9% (n=53)	45.7% (n=46)	41.7% (n=36)	32.1% (n=109)	
Nidek	88.2% (n=17)	61.2% (n=152)		54.3% (n=164)		38.1% (n=425)	
Summit	46.4% (n=28)	54.7% (n=53)	41.7% (n=48)	47.7% (n=44)	50.0% (n=52)	37.8% (n=37)	32.0% (n=147)
VISX	59.0% (n=39)	51.7% (n=58)	65.2% (n=89)	64.3% (n=84)	45.1% (n=82)	51.1% (n=94)	43.0% (n=200)

Uncorrected Vision 20/40 or Better at 6 Months Post-op Based on Initial Prescription

n=number of eyes treated

	-1.00 to -1.99D	-2.00 to -2.99D	-3.00 to -3.99D	-4.00 to -4.99D	-5.00 to -5.99D	-6.00 to -6.99D	-7.00D and above
Autonomous Ladarvision*	96.6% (n=29)	93.8% (n=64)	95.7% (n=47)	92.3% (n=52)	78.4% (n=37)	88.9% (n=18)	96.2% (n=53)
B+L Technolas 217**	100% (n=21)	100% (n=73)	100% (n=80)	98.8% (n=81)	100% (n=57)	97.5% (n=40)	100% (n=10)
LaserSight	100% (n=9)	87.9% (n=33)	90.6% (n=53)	80.4% (n=46)	77.8% (n=36)	32.1% (n=114)	
Nidek	94.1% (n=17)	86.2% (n=152)		86.6% (n=164)		82.6% (n=425)	
Summit	92.9% (n=28)	94.3% (n=53)	91.7% (n=48)	95.5% (n=44)	98.1% (n=52)	86.5% (n=37)	88.4% (n=147)
VISX	97.4% (n=39)	96.6% (n=58)	98.9% (n=89)	95.2% (n=84)	96.3% (n=82)	94.7% (n=94)	91.5% (n=200)

All Prescriptions 20/20 or better 20/40 or better

B+L Technolas* 3 month	84.8%	95.1%	In the Bausch & Lomb study 2 eyes lost two lines of vision (0.3 % of entire group).
B+L Technolas* 6 month	87.3%	99.7%	